ID   COMP_HUMAN              Reviewed;         757 AA.
AC   P49747; B4DKJ3; O14592; Q16388; Q16389; Q2NL86; Q8N4T2;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   14-OCT-2008, sequence version 2.
DT   22-JUL-2015, entry version 160.
DE   RecName: Full=Cartilage oligomeric matrix protein;
DE            Short=COMP;
DE   AltName: Full=Thrombospondin-5;
DE            Short=TSP5;
DE   Flags: Precursor;
GN   Name=COMP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ASP-50; TRP-51;
RP   GLY-109; GLY-224 AND PRO-285.
RC   TISSUE=Cartilage;
RX   PubMed=7713493; DOI=10.1006/geno.1994.1649;
RA   Newton G., Weremowicz S., Morton C.C., Copeland N.G., Gilbert D.J.,
RA   Jenkins N.A., Lawler J.;
RT   "Characterization of human and mouse cartilage oligomeric matrix
RT   protein.";
RL   Genomics 24:435-439(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ASP-50; TRP-51;
RP   GLY-109; GLY-224 AND PRO-285.
RA   Hashimoto Y., Mori H.;
RT   "Human comp cDNA with 5 SNIPs.";
RL   Submitted (JUN-2002) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 326-344, VARIANT EDM1 TYR-342,
RP   AND VARIANT PSACH ARG-328.
RX   PubMed=7670472; DOI=10.1038/ng0795-330;
RA   Briggs M.D., Hoffman S.M.G., King L.M., Olsen A.S., Mohrenweiser H.,
RA   Leroy J.G., Mortier G.R., Rimoin D.L., Lachman R.S., Gaines E.S.,
RA   Cekleniak J.A., Knowlton R.G., Cohn D.H.;
RT   "Pseudoachondroplasia and multiple epiphyseal dysplasia due to
RT   mutations in the cartilage oligomeric matrix protein gene.";
RL   Nat. Genet. 10:330-336(1995).
RN   [8]
RP   PROTEIN SEQUENCE OF 80-89, SUBUNIT, CALCIUM-BINDING, AND
RP   CHARACTERIZATION OF VARIANT PSACH ASP-469 DEL.
RX   PubMed=10852928; DOI=10.1074/jbc.M909780199;
RA   Chen H., Deere M., Hecht J.T., Lawler J.;
RT   "Cartilage oligomeric matrix protein is a calcium-binding protein, and
RT   a mutation in its type 3 repeats causes conformational changes.";
RL   J. Biol. Chem. 275:26538-26544(2000).
RN   [9]
RP   PROTEIN SEQUENCE, CALCIUM-BINDING, INTERACTION WITH COLLAGEN I;
RP   COLLAGEN II AND COLLAGEN IX, CHARACTERIZATION OF VARIANT PSACH ASP-469
RP   DEL, AND CHARACTERIZATION OF VARIANT EDM1 TYR-361.
RX   PubMed=11084047; DOI=10.1074/jbc.M009512200;
RA   Thur J., Rosenberg K., Nitsche D.P., Pihlajamaa T., Ala-Kokko L.,
RA   Heinegaard D., Paulsson M., Maurer P.;
RT   "Mutations in cartilage oligomeric matrix protein causing
RT   pseudoachondroplasia and multiple epiphyseal dysplasia affect binding
RT   of calcium and collagen I, II, and IX.";
RL   J. Biol. Chem. 276:6083-6092(2001).
RN   [10]
RP   INTERACTION WITH FN1.
RX   PubMed=12225811; DOI=10.1016/S0945-053X(02)00015-X;
RA   Di Cesare P.E., Chen F.S., Moergelin M., Carlson C.S., Leslie M.P.,
RA   Perris R., Fang C.;
RT   "Matrix-matrix interaction of cartilage oligomeric matrix protein and
RT   fibronectin.";
RL   Matrix Biol. 21:461-470(2002).
RN   [11]
RP   INTERACTION WITH MATN1; MATN3 AND MATN4.
RX   PubMed=15075323; DOI=10.1074/jbc.M403778200;
RA   Mann H.H., Oezbek S., Engel J., Paulsson M., Wagener R.;
RT   "Interactions between the cartilage oligomeric matrix protein and
RT   matrilins. Implications for matrix assembly and the pathogenesis of
RT   chondrodysplasias.";
RL   J. Biol. Chem. 279:25294-25298(2004).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH ITGB3 AND ITGA5.
RX   PubMed=16051604; DOI=10.1074/jbc.M504778200;
RA   Chen F.-H., Thomas A.O., Hecht J.T., Goldring M.B., Lawler J.;
RT   "Cartilage oligomeric matrix protein/thrombospondin 5 supports
RT   chondrocyte attachment through interaction with integrins.";
RL   J. Biol. Chem. 280:32655-32661(2005).
RN   [13]
RP   FUNCTION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RX   PubMed=16542502; DOI=10.1186/ar1922;
RA   Koelling S., Clauditz T.S., Kaste M., Miosge N.;
RT   "Cartilage oligomeric matrix protein is involved in human limb
RT   development and in the pathogenesis of osteoarthritis.";
RL   Arthritis Res. Ther. 8:R56-R56(2006).
RN   [14]
RP   INTERACTION WITH ADAMTS12.
RX   PubMed=16611630; DOI=10.1074/jbc.M513433200;
RA   Liu C.-J., Kong W., Xu K., Luan Y., Ilalov K., Sehgal B., Yu S.,
RA   Howell R.D., Di Cesare P.E.;
RT   "ADAMTS-12 associates with and degrades cartilage oligomeric matrix
RT   protein.";
RL   J. Biol. Chem. 281:15800-15808(2006).
RN   [15]
RP   INTERACTION WITH ACAN; HEPARIN; HEPARAN SULFATE AND CHONDROITIN
RP   SULFATE.
RX   PubMed=17588949; DOI=10.1074/jbc.M611390200;
RA   Chen F.-H., Herndon M.E., Patel N., Hecht J.T., Tuan R.S., Lawler J.;
RT   "Interaction of cartilage oligomeric matrix protein/thrombospondin 5
RT   with aggrecan.";
RL   J. Biol. Chem. 282:24591-24598(2007).
RN   [16]
RP   FUNCTION, AND DOMAINS.
RX   PubMed=17993464; DOI=10.1074/jbc.M704035200;
RA   Gagarina V., Carlberg A.L., Pereira-Mouries L., Hall D.J.;
RT   "Cartilage oligomeric matrix protein protects cells against death by
RT   elevating members of the IAP family of survival proteins.";
RL   J. Biol. Chem. 283:648-659(2008).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (3.15 ANGSTROMS) OF 225-757 IN COMPLEX WITH
RP   CALCIUM IONS, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-742.
RX   PubMed=19276170; DOI=10.1096/fj.08-128090;
RA   Tan K., Duquette M., Joachimiak A., Lawler J.;
RT   "The crystal structure of the signature domain of cartilage oligomeric
RT   matrix protein: implications for collagen, glycosaminoglycan and
RT   integrin binding.";
RL   FASEB J. 23:2490-2501(2009).
RN   [19]
RP   VARIANTS PSACH SER-459 DEL; TYR-468 AND TYR-472.
RX   PubMed=7670471; DOI=10.1038/ng0795-325;
RA   Hecht J.T., Nelson L.D., Crowder E., Wang Y., Elder F.F.B.,
RA   Harrison W.R., Francomano C.A., Prange C.K., Lennon G.G., Deere M.,
RA   Lawler J.;
RT   "Mutations in exon 17B of cartilage oligomeric matrix protein (COMP)
RT   cause pseudoachondroplasia.";
RL   Nat. Genet. 10:325-329(1995).
RN   [20]
RP   VARIANT EDM1 LYS-523.
RX   PubMed=9021009;
RX   DOI=10.1002/(SICI)1096-8628(19970211)68:4<396::AID-AJMG4>3.3.CO;2-R;
RA   Ballo R., Briggs M.D., Cohn D.H., Knowlton R.G., Beighton P.H.,
RA   Ramesar R.S.;
RT   "Multiple epiphyseal dysplasia, ribbing type: a novel point mutation
RT   in the COMP gene in a South African family.";
RL   Am. J. Med. Genet. 68:396-400(1997).
RN   [21]
RP   VARIANT EDM1 SER-371, AND VARIANT PSACH 513-VAL--LYS-516 DEL.
RX   PubMed=9184241;
RA   Susic S., McGrory J., Ahier J., Cole W.G.;
RT   "Multiple epiphyseal dysplasia and pseudoachondroplasia due to novel
RT   mutations in the calmodulin-like repeats of cartilage oligomeric
RT   matrix protein.";
RL   Clin. Genet. 51:219-224(1997).
RN   [22]
RP   VARIANTS PSACH, AND VARIANTS EDM1 SER-453 AND ARG-585.
RX   PubMed=9463320; DOI=10.1086/301713;
RA   Briggs M.D., Mortier G.R., Cole W.G., King L.M., Golik S.S.,
RA   Bonaventure J., Nuytinck L., de Paepe A., Leroy J.G., Biesecker L.,
RA   Lipson M., Wilcox W.R., Lachman R.S., Rimoin D.L., Knowlton R.G.,
RA   Cohn D.H.;
RT   "Diverse mutations in the gene for cartilage oligomeric matrix protein
RT   in the pseudoachondroplasia-multiple epiphyseal dysplasia disease
RT   spectrum.";
RL   Am. J. Hum. Genet. 62:311-319(1998).
RN   [23]
RP   VARIANTS PSACH AND EDM1.
RX   PubMed=9921895; DOI=10.1007/s004390050883;
RA   Ikegawa S., Ohashi H., Nishimura G., Kim K.C., Sannohe A.,
RA   Kimizuka M., Fukushima Y., Nagai T., Nakamura Y.;
RT   "Novel and recurrent COMP (cartilage oligomeric matrix protein)
RT   mutations in pseudoachondroplasia and multiple epiphyseal dysplasia.";
RL   Hum. Genet. 103:633-638(1998).
RN   [24]
RP   VARIANTS PSACH ARG-328; ASP-372 DEL; 391-PRO--ASP-394 DELINS VAL;
RP   ARG-440; SER-459 DEL; TYR-468; ASP-469 DEL AND TYR-472, AND VARIANTS
RP   EDM1 TYR-342; TYR-361; 367-ARG-GLY-368 DEL AND TYR-408.
RX   PubMed=9452026;
RA   Loughlin J., Irven C., Mustafa Z., Briggs M.D., Carr A., Lynch S.-A.,
RA   Knowlton R.G., Cohn D.H., Sykes B.;
RT   "Identification of five novel mutations in cartilage oligomeric matrix
RT   protein gene in pseudoachondroplasia and multiple epiphyseal
RT   dysplasia.";
RL   Hum. Mutat. Suppl. 1:S10-S17(1998).
RN   [25]
RP   VARIANT PSACH GLY-482.
RX   PubMed=9452063;
RA   Susic S., Ahier J., Cole W.G.;
RT   "Pseudoachondroplasia due to the substitution of the highly conserved
RT   Asp482 by Gly in the seventh calmodulin-like repeat of cartilage
RT   oligomeric matrix protein.";
RL   Hum. Mutat. Suppl. 1:S125-S127(1998).
RN   [26]
RP   VARIANT PSACH ARG-348.
RX   PubMed=11746045; DOI=10.1002/ajmg.10062;
RA   Unger S., Koerkkoe J., Krakow D., Lachman R.S., Rimoin D.L.,
RA   Cohn D.H.;
RT   "Double heterozygosity for pseudoachondroplasia and spondyloepiphyseal
RT   dysplasia congenita.";
RL   Am. J. Med. Genet. 104:140-146(2001).
RN   [27]
RP   VARIANT PSACH ASP-719.
RX   PubMed=11746044; DOI=10.1002/ajmg.10067;
RA   Mabuchi A., Haga N., Ikeda T., Manabe N., Ohashi H., Takatori Y.,
RA   Nakamura K., Ikegawa S.;
RT   "Novel mutation in exon 18 of the cartilage oligomeric matrix protein
RT   gene causes a severe pseudoachondroplasia.";
RL   Am. J. Med. Genet. 104:135-139(2001).
RN   [28]
RP   VARIANTS EDM1 ARG-276; ALA-420 AND MET-585.
RX   PubMed=11565064; DOI=10.1086/324023;
RA   Czarny-Ratajczak M., Lohiniva J., Rogala P., Kozlowski K.,
RA   Peraelae M., Carter L., Spector T.D., Kolodziej L., Seppaenen U.,
RA   Glazar R., Krolewski J., Latos-Bielenska A., Ala-Kokko L.;
RT   "A mutation in COL9A1 causes multiple epiphyseal dysplasia: further
RT   evidence for locus heterogeneity.";
RL   Am. J. Hum. Genet. 69:969-980(2001).
RN   [29]
RP   VARIANTS PSACH SER-234; GLY-290; ARG-299; TYR-326; 341-GLU-ASP-342
RP   DEL; 350-ASN--ASP-372 DEL; VAL-378; ARG-387; 402-GLY--GLY-404 DELINS
RP   VAL-CYS; ARG-440; ASN-446; SER-448; ASP-473 DEL; HIS-473; ASN-475;
RP   GLY-482; GLY-507; GLY-511; GLY-515; ILE-529; ARG-585 AND SER-719,
RP   VARIANTS EDM1 GLU-167; ARG-276; LEU-298; ASP-311; GLY-317; GLY-326;
RP   PHE-348; SER-371; TYR-371; ASN-374; ASN-376; ASN-385; ASP-385 DEL;
RP   TYR-385; HIS-397; ARG-404; TYR-410; LYS-415; GLU-427; 430-CYS--SER-432
RP   DELINS LEU-TRP-CYS; GLU-457 DEL; ASP-473 INS; ASP-501; LYS-523;
RP   MET-585; PRO-718 AND TRP-718, AND VARIANT ARG-756.
RX   PubMed=21922596; DOI=10.1002/humu.21611;
RA   Jackson G.C., Mittaz-Crettol L., Taylor J.A., Mortier G.R.,
RA   Spranger J., Zabel B., Le Merrer M., Cormier-Daire V., Hall C.M.,
RA   Offiah A., Wright M.J., Savarirayan R., Nishimura G., Ramsden S.C.,
RA   Elles R., Bonafe L., Superti-Furga A., Unger S., Zankl A.,
RA   Briggs M.D.;
RT   "Pseudoachondroplasia and multiple epiphyseal dysplasia: A 7-year
RT   comprehensive analysis of the known disease genes identify novel and
RT   recurrent mutations and provides an accurate assessment of their
RT   relative contribution.";
RL   Hum. Mutat. 33:144-157(2012).
CC   -!- FUNCTION: May play a role in the structural integrity of cartilage
CC       via its interaction with other extracellular matrix proteins such
CC       as the collagens and fibronectin. Can mediate the interaction of
CC       chondrocytes with the cartilage extracellular matrix through
CC       interaction with cell surface integrin receptors. Could play a
CC       role in the pathogenesis of osteoarthritis. Potent suppressor of
CC       apoptosis in both primary chondrocytes and transformed cells.
CC       Suppresses apoptosis by blocking the activation of caspase-3 and
CC       by inducing the IAP family of survival proteins (BIRC3, BIRC2,
CC       BIRC5 and XIAP). Essential for maintaining a vascular smooth
CC       muscle cells (VSMCs) contractile/differentiated phenotype under
CC       physiological and pathological stimuli. Maintains this phenotype
CC       of VSMCs by interacting with ITGA7 (By similarity). {ECO:0000250}.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC       Note=Binds 11-14 calcium ions per subunit.;
CC   -!- SUBUNIT: Pentamer; disulfide-linked. Exists in a more compact
CC       conformation in the presence of calcium and shows a more extended
CC       conformation in the absence of calcium. Interacts with ITGB3,
CC       ITGA5 and FN1. Binding to FN1 requires the presence of divalent
CC       cations (Ca(2+), Mg(2+) or Mn(2+)). The greatest amount of binding
CC       is seen in the presence of Mn(2+). Interacts with MATN1, MATN3,
CC       MATN4 and ACAN. Binds heparin, heparan sulfate and chondroitin
CC       sulfate. EDTA dimishes significantly its binding to ACAN and
CC       abolishes its binding to MATN3, MATN4 and chondroitin sulfate.
CC       Interacts with collagen I, II and IX, and interaction with these
CC       collagens is dependent on the presence of zinc ions. Interacts
CC       with ADAMTS12. Interacts with ITGA7 (By similarity).
CC       {ECO:0000250}.
CC   -!- INTERACTION:
CC       P13608:ACAN (xeno); NbExp=2; IntAct=EBI-2531022, EBI-6259246;
CC       P58397:ADAMTS12; NbExp=3; IntAct=EBI-2531022, EBI-9028051;
CC       P32242:OTX1; NbExp=3; IntAct=EBI-2531022, EBI-740446;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P49747-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P49747-2; Sequence=VSP_055758;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Abundantly expressed in the chondrocyte
CC       extracellular matrix, and is also found in bone, tendon, ligament
CC       and synovium and blood vessels. Increased amounts are produced
CC       during late stages of osteoarthritis in the area adjacent to the
CC       main defect. {ECO:0000269|PubMed:16542502}.
CC   -!- DEVELOPMENTAL STAGE: Present during the earliest stages of limb
CC       maturation and is later found in regions where the joints develop.
CC       {ECO:0000269|PubMed:16542502}.
CC   -!- DOMAIN: The cell attachment motif mediates the attachment to
CC       chondrocytes. It mediates the induction of both the IAP family of
CC       survival proteins and the antiapoptotic response.
CC       {ECO:0000269|PubMed:17993464}.
CC   -!- DOMAIN: The TSP C-terminal domain mediates interaction with FN1
CC       and ACAN. {ECO:0000269|PubMed:17993464}.
CC   -!- DOMAIN: Each of the eight TSP type-3 repeats binds two calcium
CC       ions. The TSP C-terminal domain binds three calcium ions.
CC       {ECO:0000269|PubMed:17993464}.
CC   -!- DISEASE: Multiple epiphyseal dysplasia 1 (EDM1) [MIM:132400]: A
CC       generalized skeletal dysplasia associated with significant
CC       morbidity. Joint pain, joint deformity, waddling gait, and short
CC       stature are the main clinical signs and symptoms. Radiological
CC       examination of the skeleton shows delayed, irregular
CC       mineralization of the epiphyseal ossification centers and of the
CC       centers of the carpal and tarsal bones. Multiple epiphyseal
CC       dysplasia is broadly categorized into the more severe Fairbank and
CC       the milder Ribbing types. The Fairbank type is characterized by
CC       shortness of stature, short and stubby fingers, small epiphyses in
CC       several joints, including the knee, ankle, hand, and hip. The
CC       Ribbing type is confined predominantly to the hip joints and is
CC       characterized by hands that are normal and stature that is normal
CC       or near-normal. {ECO:0000269|PubMed:11565064,
CC       ECO:0000269|PubMed:21922596, ECO:0000269|PubMed:7670472,
CC       ECO:0000269|PubMed:9021009, ECO:0000269|PubMed:9184241,
CC       ECO:0000269|PubMed:9452026, ECO:0000269|PubMed:9463320,
CC       ECO:0000269|PubMed:9921895}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Pseudoachondroplasia (PSACH) [MIM:177170]: A skeletal
CC       dysplasia usually manifesting in the second year of life and
CC       characterized by moderate to severe disproportionate short
CC       stature, deformity of the lower limbs, brachydactyly, ligamentous
CC       laxity, and degenerative joint disease.
CC       {ECO:0000269|PubMed:11746044, ECO:0000269|PubMed:11746045,
CC       ECO:0000269|PubMed:21922596, ECO:0000269|PubMed:7670471,
CC       ECO:0000269|PubMed:7670472, ECO:0000269|PubMed:9184241,
CC       ECO:0000269|PubMed:9452026, ECO:0000269|PubMed:9452063,
CC       ECO:0000269|PubMed:9463320}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the thrombospondin family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 4 EGF-like domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00076}.
CC   -!- SIMILARITY: Contains 1 TSP C-terminal (TSPC) domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00635}.
CC   -!- SIMILARITY: Contains 8 TSP type-3 repeats. {ECO:0000255|PROSITE-
CC       ProRule:PRU00634}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB86501.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L32137; AAA57253.1; -; mRNA.
DR   EMBL; AB086984; BAC53888.1; -; mRNA.
DR   EMBL; AK296586; BAG59205.1; -; mRNA.
DR   EMBL; AC003107; AAB86501.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; CH471106; EAW84737.1; -; Genomic_DNA.
DR   EMBL; BC110847; AAI10848.1; -; mRNA.
DR   EMBL; BC125092; AAI25093.1; -; mRNA.
DR   EMBL; S79499; AAB35269.1; -; Genomic_DNA.
DR   EMBL; S79500; AAB35270.1; -; Genomic_DNA.
DR   CCDS; CCDS12385.1; -. [P49747-1]
DR   RefSeq; NP_000086.2; NM_000095.2. [P49747-1]
DR   UniGene; Hs.1584; -.
DR   PDB; 3FBY; X-ray; 3.15 A; A/B/C=225-757.
DR   PDBsum; 3FBY; -.
DR   ProteinModelPortal; P49747; -.
DR   SMR; P49747; 29-72, 91-757.
DR   BioGrid; 107706; 1.
DR   IntAct; P49747; 5.
DR   STRING; 9606.ENSP00000222271; -.
DR   PhosphoSite; P49747; -.
DR   BioMuta; COMP; -.
DR   DMDM; 209572601; -.
DR   MaxQB; P49747; -.
DR   PaxDb; P49747; -.
DR   PRIDE; P49747; -.
DR   DNASU; 1311; -.
DR   Ensembl; ENST00000222271; ENSP00000222271; ENSG00000105664.
DR   Ensembl; ENST00000425807; ENSP00000403792; ENSG00000105664. [P49747-2]
DR   GeneID; 1311; -.
DR   KEGG; hsa:1311; -.
DR   UCSC; uc002nkd.3; human. [P49747-1]
DR   UCSC; uc010xqj.2; human.
DR   CTD; 1311; -.
DR   GeneCards; GC19M018894; -.
DR   GeneReviews; COMP; -.
DR   H-InvDB; HIX0014925; -.
DR   HGNC; HGNC:2227; COMP.
DR   MIM; 132400; phenotype.
DR   MIM; 177170; phenotype.
DR   MIM; 600310; gene.
DR   neXtProt; NX_P49747; -.
DR   Orphanet; 93308; Multiple epiphyseal dysplasia type 1.
DR   Orphanet; 750; Pseudoachondroplasia.
DR   PharmGKB; PA26744; -.
DR   eggNOG; NOG12793; -.
DR   GeneTree; ENSGT00800000124017; -.
DR   HOGENOM; HOG000007542; -.
DR   HOVERGEN; HBG000636; -.
DR   InParanoid; P49747; -.
DR   KO; K04659; -.
DR   OMA; PEDYETQ; -.
DR   PhylomeDB; P49747; -.
DR   TreeFam; TF324917; -.
DR   Reactome; REACT_13552; Integrin cell surface interactions.
DR   Reactome; REACT_163906; ECM proteoglycans.
DR   ChiTaRS; COMP; human.
DR   EvolutionaryTrace; P49747; -.
DR   GeneWiki; Cartilage_oligomeric_matrix_protein; -.
DR   GenomeRNAi; 1311; -.
DR   NextBio; 35472801; -.
DR   PMAP-CutDB; P49747; -.
DR   PRO; PR:P49747; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; P49747; -.
DR   CleanEx; HS_COMP; -.
DR   ExpressionAtlas; P49747; baseline and differential.
DR   Genevisible; P49747; HS.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; TAS:ProtInc.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0005518; F:collagen binding; IDA:UniProtKB.
DR   GO; GO:0005201; F:extracellular matrix structural constituent; TAS:ProtInc.
DR   GO; GO:0043395; F:heparan sulfate proteoglycan binding; IDA:UniProtKB.
DR   GO; GO:0008201; F:heparin binding; IDA:UniProtKB.
DR   GO; GO:0002020; F:protease binding; IPI:BHF-UCL.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0003417; P:growth plate cartilage development; IEA:Ensembl.
DR   GO; GO:0060173; P:limb development; IDA:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0009887; P:organ morphogenesis; TAS:ProtInc.
DR   GO; GO:0001501; P:skeletal system development; TAS:ProtInc.
DR   Gene3D; 2.60.120.200; -; 1.
DR   Gene3D; 4.10.1080.10; -; 2.
DR   InterPro; IPR028492; Comp.
DR   InterPro; IPR013320; ConA-like_dom.
DR   InterPro; IPR000742; EG-like_dom.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR009030; Growth_fac_rcpt_N_dom.
DR   InterPro; IPR024665; Thbs/COMP_coiled-coil.
DR   InterPro; IPR003367; Thrombospondin_3-like_rpt.
DR   InterPro; IPR017897; Thrombospondin_3_rpt.
DR   InterPro; IPR008859; Thrombospondin_C.
DR   InterPro; IPR028974; TSP_type-3_rpt.
DR   PANTHER; PTHR10199:SF81; PTHR10199:SF81; 1.
DR   Pfam; PF11598; COMP; 1.
DR   Pfam; PF07645; EGF_CA; 2.
DR   Pfam; PF02412; TSP_3; 6.
DR   Pfam; PF05735; TSP_C; 1.
DR   SMART; SM00181; EGF; 2.
DR   SMART; SM00179; EGF_CA; 2.
DR   SUPFAM; SSF103647; SSF103647; 3.
DR   SUPFAM; SSF49899; SSF49899; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS50026; EGF_3; 3.
DR   PROSITE; PS01187; EGF_CA; 2.
DR   PROSITE; PS51234; TSP3; 8.
DR   PROSITE; PS51236; TSP_CTER; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; Calcium; Cell adhesion;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Dwarfism; EGF-like domain; Extracellular matrix;
KW   Glycoprotein; Heparin-binding; Polymorphism; Reference proteome;
KW   Repeat; Secreted; Signal.
FT   SIGNAL        1     20       {ECO:0000255}.
FT   CHAIN        21    757       Cartilage oligomeric matrix protein.
FT                                /FTId=PRO_0000035857.
FT   DOMAIN       87    126       EGF-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      127    179       EGF-like 2; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      180    222       EGF-like 3; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      225    267       EGF-like 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REPEAT      268    300       TSP type-3 1.
FT   REPEAT      301    336       TSP type-3 2.
FT   REPEAT      337    359       TSP type-3 3.
FT   REPEAT      360    395       TSP type-3 4.
FT   REPEAT      396    418       TSP type-3 5.
FT   REPEAT      419    456       TSP type-3 6.
FT   REPEAT      457    492       TSP type-3 7.
FT   REPEAT      493    528       TSP type-3 8.
FT   DOMAIN      532    746       TSP C-terminal. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00635}.
FT   REGION       22     86       COMP N-terminal.
FT   REGION      527    757       Mediates cell survival and induction of
FT                                the IAP family of survival proteins.
FT   MOTIF       367    369       Cell attachment site. {ECO:0000255}.
FT   CARBOHYD    121    121       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    742    742       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19276170}.
FT   DISULFID     69     69       Interchain.
FT                                {ECO:0000305|PubMed:19276170}.
FT   DISULFID     72     72       Interchain.
FT                                {ECO:0000305|PubMed:19276170}.
FT   DISULFID     91    102       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID     96    111       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    114    125       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    131    142       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    136    151       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    154    178       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    184    197       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    191    206       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    209    221       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    229    243       {ECO:0000255|PROSITE-ProRule:PRU00076,
FT                                ECO:0000269|PubMed:19276170}.
FT   DISULFID    237    253       {ECO:0000255|PROSITE-ProRule:PRU00076,
FT                                ECO:0000269|PubMed:19276170}.
FT   DISULFID    255    266       {ECO:0000255|PROSITE-ProRule:PRU00076,
FT                                ECO:0000269|PubMed:19276170}.
FT   DISULFID    282    287       {ECO:0000255|PROSITE-ProRule:PRU00076,
FT                                ECO:0000269|PubMed:19276170}.
FT   DISULFID    292    312       {ECO:0000255|PROSITE-ProRule:PRU00076,
FT                                ECO:0000269|PubMed:19276170}.
FT   DISULFID    328    348       {ECO:0000255|PROSITE-ProRule:PRU00076,
FT                                ECO:0000269|PubMed:19276170}.
FT   DISULFID    351    371       {ECO:0000255|PROSITE-ProRule:PRU00076,
FT                                ECO:0000269|PubMed:19276170}.
FT   DISULFID    387    407       {ECO:0000255|PROSITE-ProRule:PRU00076,
FT                                ECO:0000269|PubMed:19276170}.
FT   DISULFID    410    430       {ECO:0000255|PROSITE-ProRule:PRU00076,
FT                                ECO:0000269|PubMed:19276170}.
FT   DISULFID    448    468       {ECO:0000255|PROSITE-ProRule:PRU00076,
FT                                ECO:0000269|PubMed:19276170}.
FT   DISULFID    484    504       {ECO:0000255|PROSITE-ProRule:PRU00076,
FT                                ECO:0000269|PubMed:19276170}.
FT   DISULFID    520    741       {ECO:0000255|PROSITE-ProRule:PRU00076,
FT                                ECO:0000269|PubMed:19276170}.
FT   VAR_SEQ     129    181       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_055758.
FT   VARIANT      50     50       E -> D. {ECO:0000269|PubMed:7713493,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_016254.
FT   VARIANT      51     51       L -> W. {ECO:0000269|PubMed:7713493,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_016255.
FT   VARIANT     109    109       A -> G. {ECO:0000269|PubMed:7713493,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_016257.
FT   VARIANT     167    167       G -> E (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066789.
FT   VARIANT     224    224       R -> G. {ECO:0000269|PubMed:7713493,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_016258.
FT   VARIANT     234    234       P -> S (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066790.
FT   VARIANT     276    276       P -> R (in EDM1).
FT                                {ECO:0000269|PubMed:11565064,
FT                                ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_026239.
FT   VARIANT     285    285       R -> P. {ECO:0000269|PubMed:7713493,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_016261.
FT   VARIANT     290    290       D -> G (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066791.
FT   VARIANT     290    290       D -> N (in PSACH; mild form).
FT                                /FTId=VAR_007614.
FT   VARIANT     298    298       S -> L (in EDM1; phenotypic features
FT                                overlapping with mild PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066792.
FT   VARIANT     299    299       G -> R (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_007615.
FT   VARIANT     311    311       A -> D (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066793.
FT   VARIANT     317    317       D -> G (in EDM1; atypical form).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066794.
FT   VARIANT     326    326       D -> G (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066795.
FT   VARIANT     326    326       D -> Y (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066796.
FT   VARIANT     328    328       C -> R (in PSACH; mild form).
FT                                {ECO:0000269|PubMed:7670472,
FT                                ECO:0000269|PubMed:9452026}.
FT                                /FTId=VAR_007616.
FT   VARIANT     341    342       Missing (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066797.
FT   VARIANT     342    342       D -> Y (in EDM1; Fairbank type).
FT                                {ECO:0000269|PubMed:7670472,
FT                                ECO:0000269|PubMed:9452026}.
FT                                /FTId=VAR_007617.
FT   VARIANT     348    348       C -> F (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066798.
FT   VARIANT     348    348       C -> R (in PSACH).
FT                                {ECO:0000269|PubMed:11746045}.
FT                                /FTId=VAR_017102.
FT   VARIANT     349    349       D -> V (in PSACH; mild form).
FT                                /FTId=VAR_007618.
FT   VARIANT     350    372       Missing (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066799.
FT   VARIANT     361    361       D -> V (in EDM1; Fairbank type).
FT                                /FTId=VAR_007619.
FT   VARIANT     361    361       D -> Y (in EDM1; binds less calcium).
FT                                {ECO:0000269|PubMed:11084047,
FT                                ECO:0000269|PubMed:9452026}.
FT                                /FTId=VAR_007620.
FT   VARIANT     367    368       Missing (in EDM1).
FT                                {ECO:0000269|PubMed:9452026}.
FT                                /FTId=VAR_007621.
FT   VARIANT     371    371       C -> S (in EDM1; Fairbank type).
FT                                {ECO:0000269|PubMed:21922596,
FT                                ECO:0000269|PubMed:9184241}.
FT                                /FTId=VAR_007622.
FT   VARIANT     371    371       C -> Y (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066800.
FT   VARIANT     372    372       Missing (in PSACH).
FT                                {ECO:0000269|PubMed:9452026}.
FT                                /FTId=VAR_007623.
FT   VARIANT     374    374       D -> N (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066801.
FT   VARIANT     374    374       Missing (in PSACH; mild form).
FT                                /FTId=VAR_007624.
FT   VARIANT     376    376       D -> N (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066802.
FT   VARIANT     378    378       D -> V (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066803.
FT   VARIANT     381    381       R -> C (in dbSNP:rs3179763).
FT                                /FTId=VAR_046796.
FT   VARIANT     385    385       D -> N (in EDM1; atypical form).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066804.
FT   VARIANT     385    385       D -> Y (in EDM1; atypical form).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066805.
FT   VARIANT     385    385       Missing (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066806.
FT   VARIANT     387    387       C -> G (in PSACH; mild form).
FT                                /FTId=VAR_007625.
FT   VARIANT     387    387       C -> R (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066807.
FT   VARIANT     391    394       PNSD -> V (in PSACH).
FT                                {ECO:0000269|PubMed:9452026}.
FT                                /FTId=VAR_007626.
FT   VARIANT     397    397       D -> H (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066808.
FT   VARIANT     402    404       GIG -> VC (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066809.
FT   VARIANT     404    404       G -> R (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066810.
FT   VARIANT     408    408       D -> Y (in EDM1).
FT                                {ECO:0000269|PubMed:9452026}.
FT                                /FTId=VAR_007627.
FT   VARIANT     410    410       C -> Y (in EDM1; phenotype overlapping
FT                                with mild PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066811.
FT   VARIANT     415    415       N -> K (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066812.
FT   VARIANT     420    420       D -> A (in EDM1).
FT                                {ECO:0000269|PubMed:11565064}.
FT                                /FTId=VAR_026240.
FT   VARIANT     427    427       G -> E (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066813.
FT   VARIANT     430    432       CDS -> LWC (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066814.
FT   VARIANT     440    440       G -> E (in PSACH; mild form).
FT                                /FTId=VAR_007628.
FT   VARIANT     440    440       G -> R (in PSACH).
FT                                {ECO:0000269|PubMed:21922596,
FT                                ECO:0000269|PubMed:9452026}.
FT                                /FTId=VAR_007629.
FT   VARIANT     446    446       D -> N (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066815.
FT   VARIANT     448    448       C -> S (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066816.
FT   VARIANT     453    453       N -> S (in EDM1; Fairbank type;
FT                                dbSNP:rs28936668).
FT                                {ECO:0000269|PubMed:9463320}.
FT                                /FTId=VAR_007630.
FT   VARIANT     457    457       Missing (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066817.
FT   VARIANT     459    459       Missing (in PSACH; severe form).
FT                                {ECO:0000269|PubMed:7670471,
FT                                ECO:0000269|PubMed:9452026}.
FT                                /FTId=VAR_007631.
FT   VARIANT     468    468       C -> Y (in PSACH; severe form).
FT                                {ECO:0000269|PubMed:7670471,
FT                                ECO:0000269|PubMed:9452026}.
FT                                /FTId=VAR_007632.
FT   VARIANT     469    469       Missing (in PSACH; severe form; MUT3
FT                                mutant; most common mutation; binds less
FT                                calcium and causes misfolding of the
FT                                protein; greatly reduced interaction with
FT                                ACAN; reduced interaction with collagen).
FT                                {ECO:0000269|PubMed:10852928,
FT                                ECO:0000269|PubMed:11084047,
FT                                ECO:0000269|PubMed:9452026}.
FT                                /FTId=VAR_007633.
FT   VARIANT     472    472       D -> Y (in PSACH; severe form).
FT                                {ECO:0000269|PubMed:7670471,
FT                                ECO:0000269|PubMed:9452026}.
FT                                /FTId=VAR_007634.
FT   VARIANT     473    473       D -> DD (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066818.
FT   VARIANT     473    473       D -> G (in PSACH; severe form;
FT                                dbSNP:rs28936669).
FT                                /FTId=VAR_007635.
FT   VARIANT     473    473       D -> H (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066819.
FT   VARIANT     473    473       Missing (in PSACH; severe form).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_007636.
FT   VARIANT     475    475       D -> N (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066820.
FT   VARIANT     482    482       D -> G (in PSACH).
FT                                {ECO:0000269|PubMed:21922596,
FT                                ECO:0000269|PubMed:9452063}.
FT                                /FTId=VAR_007637.
FT   VARIANT     501    501       G -> D (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066821.
FT   VARIANT     507    507       D -> G (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066822.
FT   VARIANT     511    511       D -> G (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066823.
FT   VARIANT     513    516       Missing (in PSACH; mild form).
FT                                {ECO:0000269|PubMed:9184241}.
FT                                /FTId=VAR_007638.
FT   VARIANT     515    515       D -> G (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066824.
FT   VARIANT     518    518       D -> N (in PSACH; mild form).
FT                                /FTId=VAR_007639.
FT   VARIANT     523    523       N -> K (in EDM1; Ribbing type).
FT                                {ECO:0000269|PubMed:21922596,
FT                                ECO:0000269|PubMed:9021009}.
FT                                /FTId=VAR_007640.
FT   VARIANT     529    529       T -> I (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066825.
FT   VARIANT     585    585       T -> M (in PSACH; mild form and EDM1).
FT                                {ECO:0000269|PubMed:11565064,
FT                                ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_007641.
FT   VARIANT     585    585       T -> R (in EDM1 and PSACH).
FT                                {ECO:0000269|PubMed:21922596,
FT                                ECO:0000269|PubMed:9463320}.
FT                                /FTId=VAR_007642.
FT   VARIANT     718    718       R -> P (in EDM1).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066826.
FT   VARIANT     718    718       R -> W (in EDM1; dbSNP:rs28936368).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066827.
FT   VARIANT     719    719       G -> D (in PSACH; severe).
FT                                {ECO:0000269|PubMed:11746044}.
FT                                /FTId=VAR_017103.
FT   VARIANT     719    719       G -> S (in PSACH).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066828.
FT   VARIANT     756    756       Q -> R (in a patient with multiple
FT                                epiphyseal dysplasia; dbSNP:rs61752496).
FT                                {ECO:0000269|PubMed:21922596}.
FT                                /FTId=VAR_066829.
FT   CONFLICT    256    256       A -> R (in Ref. 1; AAA57253 and 2;
FT                                BAC53888). {ECO:0000305}.
FT   CONFLICT    340    340       D -> Y (in Ref. 7; AAB35270).
FT                                {ECO:0000305}.
FT   STRAND      232    234       {ECO:0000244|PDB:3FBY}.
FT   STRAND      241    245       {ECO:0000244|PDB:3FBY}.
FT   STRAND      251    255       {ECO:0000244|PDB:3FBY}.
FT   STRAND      259    265       {ECO:0000244|PDB:3FBY}.
FT   STRAND      272    274       {ECO:0000244|PDB:3FBY}.
FT   HELIX       285    287       {ECO:0000244|PDB:3FBY}.
FT   STRAND      291    295       {ECO:0000244|PDB:3FBY}.
FT   STRAND      306    308       {ECO:0000244|PDB:3FBY}.
FT   HELIX       310    312       {ECO:0000244|PDB:3FBY}.
FT   TURN        314    317       {ECO:0000244|PDB:3FBY}.
FT   STRAND      319    321       {ECO:0000244|PDB:3FBY}.
FT   HELIX       323    325       {ECO:0000244|PDB:3FBY}.
FT   STRAND      327    331       {ECO:0000244|PDB:3FBY}.
FT   STRAND      342    344       {ECO:0000244|PDB:3FBY}.
FT   HELIX       346    348       {ECO:0000244|PDB:3FBY}.
FT   STRAND      364    367       {ECO:0000244|PDB:3FBY}.
FT   HELIX       369    371       {ECO:0000244|PDB:3FBY}.
FT   STRAND      378    380       {ECO:0000244|PDB:3FBY}.
FT   STRAND      401    403       {ECO:0000244|PDB:3FBY}.
FT   HELIX       405    407       {ECO:0000244|PDB:3FBY}.
FT   STRAND      424    426       {ECO:0000244|PDB:3FBY}.
FT   TURN        428    430       {ECO:0000244|PDB:3FBY}.
FT   HELIX       443    445       {ECO:0000244|PDB:3FBY}.
FT   STRAND      462    464       {ECO:0000244|PDB:3FBY}.
FT   TURN        466    468       {ECO:0000244|PDB:3FBY}.
FT   STRAND      470    473       {ECO:0000244|PDB:3FBY}.
FT   STRAND      475    477       {ECO:0000244|PDB:3FBY}.
FT   HELIX       479    481       {ECO:0000244|PDB:3FBY}.
FT   STRAND      495    500       {ECO:0000244|PDB:3FBY}.
FT   TURN        503    506       {ECO:0000244|PDB:3FBY}.
FT   STRAND      511    513       {ECO:0000244|PDB:3FBY}.
FT   HELIX       515    517       {ECO:0000244|PDB:3FBY}.
FT   STRAND      532    540       {ECO:0000244|PDB:3FBY}.
FT   STRAND      551    553       {ECO:0000244|PDB:3FBY}.
FT   TURN        555    557       {ECO:0000244|PDB:3FBY}.
FT   STRAND      560    562       {ECO:0000244|PDB:3FBY}.
FT   STRAND      567    588       {ECO:0000244|PDB:3FBY}.
FT   STRAND      596    605       {ECO:0000244|PDB:3FBY}.
FT   STRAND      608    617       {ECO:0000244|PDB:3FBY}.
FT   STRAND      625    627       {ECO:0000244|PDB:3FBY}.
FT   STRAND      636    641       {ECO:0000244|PDB:3FBY}.
FT   HELIX       648    655       {ECO:0000244|PDB:3FBY}.
FT   STRAND      656    658       {ECO:0000244|PDB:3FBY}.
FT   TURN        661    663       {ECO:0000244|PDB:3FBY}.
FT   STRAND      664    669       {ECO:0000244|PDB:3FBY}.
FT   STRAND      681    689       {ECO:0000244|PDB:3FBY}.
FT   HELIX       690    692       {ECO:0000244|PDB:3FBY}.
FT   STRAND      694    701       {ECO:0000244|PDB:3FBY}.
FT   STRAND      704    708       {ECO:0000244|PDB:3FBY}.
FT   STRAND      716    728       {ECO:0000244|PDB:3FBY}.
FT   STRAND      732    741       {ECO:0000244|PDB:3FBY}.
FT   HELIX       748    754       {ECO:0000244|PDB:3FBY}.
SQ   SEQUENCE   757 AA;  82860 MW;  A0B73AADB39FBC7B CRC64;
     MVPDTACVLL LTLAALGASG QGQSPLGSDL GPQMLRELQE TNAALQDVRE LLRQQVREIT
     FLKNTVMECD ACGMQQSVRT GLPSVRPLLH CAPGFCFPGV ACIQTESGAR CGPCPAGFTG
     NGSHCTDVNE CNAHPCFPRV RCINTSPGFR CEACPPGYSG PTHQGVGLAF AKANKQVCTD
     INECETGQHN CVPNSVCINT RGSFQCGPCQ PGFVGDQASG CQRRAQRFCP DGSPSECHEH
     ADCVLERDGS RSCVCAVGWA GNGILCGRDT DLDGFPDEKL RCPERQCRKD NCVTVPNSGQ
     EDVDRDGIGD ACDPDADGDG VPNEKDNCPL VRNPDQRNTD EDKWGDACDN CRSQKNDDQK
     DTDQDGRGDA CDDDIDGDRI RNQADNCPRV PNSDQKDSDG DGIGDACDNC PQKSNPDQAD
     VDHDFVGDAC DSDQDQDGDG HQDSRDNCPT VPNSAQEDSD HDGQGDACDD DDDNDGVPDS
     RDNCRLVPNP GQEDADRDGV GDVCQDDFDA DKVVDKIDVC PENAEVTLTD FRAFQTVVLD
     PEGDAQIDPN WVVLNQGREI VQTMNSDPGL AVGYTAFNGV DFEGTFHVNT VTDDDYAGFI
     FGYQDSSSFY VVMWKQMEQT YWQANPFRAV AEPGIQLKAV KSSTGPGEQL RNALWHTGDT
     ESQVRLLWKD PRNVGWKDKK SYRWFLQHRP QVGYIRVRFY EGPELVADSN VVLDTTMRGG
     RLGVFCFSQE NIIWANLRYR CNDTIPEDYE THQLRQA
//
